| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BECN1 |
| Entrez GeneID | 8678 |
| WB Predicted band size | Calculated MW: 52 kDa; Observed MW: 60 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Recombinant protein of human Beclin 1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3-4篇关于 **Beclin 1抗体** 的参考文献及其摘要内容：
---
1. **文献名称**：*Induction of autophagy and inhibition of tumorigenesis by beclin 1*
**作者**：Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H., & Levine, B.
**摘要**：该研究首次证明Beclin 1通过调控自噬抑制肿瘤发生，并发现其单倍剂量不足(haploinsufficiency)会导致小鼠自发肿瘤。研究中使用特异性抗体证实了Beclin 1表达水平与自噬活性及肿瘤发展的相关性。
---
2. **文献名称**：*Beclin 1 antibodies specifically detect autophagy in human cancer cells*
**作者**：Qu, X., Yu, J., Bhagat, G., Furuya, N., & Levine, B.
**摘要**：文章验证了多种Beclin 1抗体的特异性，发现其可用于检测人类癌症细胞中的自噬活性，并揭示了Beclin 1表达降低与乳腺癌等肿瘤进展的关系。
---
3. **文献名称**：*Beclin 1 and autophagy in glioblastoma: Immunohistochemical analysis*
**作者**：Miracco, C., Cevenini, G., Franchi, A., Luzi, P., Cosci, E., & Mourmouras, V.
**摘要**：通过免疫组化(使用Beclin 1抗体)分析胶质母细胞瘤组织，发现Beclin 1低表达与肿瘤恶性程度和患者不良预后显著相关，提示其作为潜在生物标志物的价值。
---
4. **文献名称**：*Characterization of a novel monoclonal antibody to Beclin 1 for autophagy studies*
**作者**：Aita, V. M., Liang, X. H., Murty, V. V., & Levine, B.
**摘要**：该研究开发了一种高特异性单克隆Beclin 1抗体，并验证其在Western blot和免疫荧光中的应用，为自噬机制研究提供了可靠工具。
---
以上文献聚焦于Beclin 1抗体的应用及其在自噬、肿瘤抑制中的功能研究，涵盖基础机制与临床关联分析。
Beclin 1. a key autophagy-related protein encoded by the *BECN1* gene in humans, plays a critical role in regulating autophagy, a cellular degradation process essential for maintaining homeostasis. Discovered in 1998 through its interaction with Bcl-2. Beclin 1 is a haploinsufficient tumor suppressor involved in diverse cellular processes, including apoptosis, endocytosis, and immune responses. Structurally, it contains a Bcl-2 homology (BH3) domain and a coiled-coil domain, enabling interactions with partners like VPS34. UVRAG, and ATG14L to form the class III PI3K complex, which drives autophagosome formation.
Antibodies targeting Beclin 1 are widely used in research to study autophagy dynamics, protein localization, and expression levels in physiological and pathological contexts. They are critical tools for techniques such as Western blotting, immunohistochemistry, and immunoprecipitation. Studies using these antibodies have revealed that dysregulated Beclin 1 expression correlates with cancer progression, neurodegenerative disorders (e.g., Alzheimer’s disease), and infectious diseases, highlighting its therapeutic potential. For instance, reduced Beclin 1 levels are linked to tumorigenesis, while its upregulation may enhance autophagic clearance of protein aggregates in neurodegeneration.
However, variability in antibody specificity (due to isoforms or post-translational modifications) necessitates careful validation. Research on Beclin 1 continues to explore its role as a biomarker or therapeutic target, emphasizing its centrality in autophagy and disease mechanisms.
×
